GlobalData
Pharma sales in AMD markets to soar by 2026, says GlobalData
According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. more
Biosimilars popularity rising and emerging markets gaining a foothold, says GlobalData
Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData. more
2018 set to be big for Duchenne muscular dystrophy deals, reveals GlobalData
This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData. more
Real-world evidence will support use of biosimilars for Crohn’s disease, notes GlobalData
According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value. more
Record breakers — biosimilar approvals soar, according to GlobalData
Data and analytics company, GlobalData, has revealed 2017 was a record-breaking year for the number of approvals of biosimilars. more
Substantial gains in market share for GLP-1 receptor agonists and SGLT-2 inhibitors, notes GlobalData
Data and analytics company, GlobalData, has observed substantial gains in market share across the seven major markets (7MM) of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. more
One flu over the chicken’s nest: Difficult flu season reinforces move away from egg-based vaccine manufacture, says GlobalData
After the US CDC released the stats for the 2017–2018 influenza season, in which there were a reported 97 influenza-related paediatric deaths, GlobalData has reiterated its belief to move away from the chicken egg-based approach to flu vaccines more
The top five tweets: From cold chain to collaborations — what did EPM readers click on this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Cases of drug-resistant epilepsy set to rise, notes GlobalData
Cases of drug-resistant epilepsy are predicted to increase by more than 100,000 by the year 2026, according to data and analytics company, GlobalData. more
GlobalData reveals findings from its 2017 review of biopharma industry
Data and analytics company, GlobalData, has released its findings from its review of the biopharmaceutical industry from 2017. more
Trial success for new DCB device may lead to a shift in the competitive landscape, says GlobalData
As a result of the outcomes of a trial comparing two drug-coated balloon (DCB) devices, in which no statistically significant patency rate difference was found, GlobalData, has indicated a potential change in the competitive landscape more
Merck set to be top in pharma licensing deals for 2018, according to GlobalData
Data and analytics company, GlobalData, has revealed its prediction that Merck will lead the way in licensing deals for the year when considering the success of the company since 2016. more
Glaucoma market will see growth due to pipeline products, says GlobalData
The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products. more
NHS should administer quadrivalent flu jabs, according to GlobalData
Administration of quadrivalent flu jabs should be on the agenda for the NHS as fourth flu strain, known as ‘Japanese flu’ is becoming most prevalent in Europe, according to data and analytics company, GlobalData. more
New not-for-profit generic company will not benefit CMO industry, says GlobalData
The new not-for-profit generic pharmaceutical company, to be created by five hospital organisations, is unlikely to benefit the contract manufacturing organisation (CMO) industry, according to data and analytics company, GlobalData. more
Pharma news round-up: What might have been missed in the run up to Christmas
With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. more
Immuno-oncology to become mainstay of cancer treatment, notes report
The latest report from business information and analytics provider, GlobalData, has indicated that immune-oncology (IO) will become the fifth pillar of cancer treatment, joining surgery, radiotherapy, chemotherapy and other targeted treatments. more
Asia Pacific region expected to grow faster in drug delivery, notes GlobalData
The research and consulting firm, GlobalData, has released a report demonstrating the expected increase in the drug delivery devices market in the Asia-Pacific (APAC) region will be larger than that of North America over the same period to 2026. more
Innovation in drug discovery the driver for pharma, notes GlobalData
Data analysis released by GlobalData has revealed that innovation in drug discovery is a driver for the pharmaceutical industry now that the age of the blockbuster appears to be at an end and research and development spending is on the up. more
Spain’s pharma market to rise slightly
Research and consulting firm, GlobalData, has released a report demonstrating that the Spanish pharmaceutical market is set to see a slight rise in value from $23.7 billion last year to $25.1 billion by the year 2021. more
